As many as 4.28 lakh shares were traded on the BSE.

The counter has recovered after declining for a prolonged period from from late June to earlier August. From Rs 92.35 on 29 June, it declined to Rs 72.55 by 7 August. Here, it found support and advanced to Rs 89.05 on 18 August 2006.

At the current market price of Rs 98.90, Wanbury trades at 10 times its Q1 June 2006 annualized EPS of Rs 9.73.

Wanbury announced that the US FDA has renewed its approval for the company's multi-product API facility at Patalganga, from where it will manufacture three new products -- Tramadol, Amytriptyline and Paroxetine. The Patalganga plant had received the US FDA approval earlier in 2002. It will continue to manufacture Metformin and Salsalate.

As per reports in July, Wanbury, which had recently acquired Doctors Organic Chemicals (DOCL) and Pharmaceutical Products of India (PPIL), is in an advanced stage of merging these two companies into itself.

As per reports in May, Wanbury is also in an advance stage of acquiring a branded generics company in the UK. Wanbury's investment in the overseas deal is expected to be in the range of $20 to $25 million.

Wanbury had commissioned a new unit in April at its recently acquired facility at Tanuku, Andhra Pradesh. With this capacity expansion, estimated at a cost of Rs 25 crore, the company expects to add more than Rs 100 crore to its topline. The Tanuku facility has a multi-product approval from the US Food and Drug Administration (USFDA), and has also undergone plant inspections by leading MNCs for outsourcing various products.

Wanbury registered a net profit growth of 3% to Rs 3.10 crore (Rs 3.01 crore) in Q1 June 2006. Net sales rose 40.9% to Rs 27.38 crore (Rs 19.43 crore).

Wanbury is a merged entity of Pearl Organics and Wander, an erstwhile subsidiary of Sandoz. With this merger, the consolidated entity - Wanbury - has emerged as an integrated pharmaceutical company offering bulk drugs and formulations under one roof.

Last year, the company raised Rs 440.2 crore through the issue of 10.87 lakh Global Depository Receipts (GDR) at an offer price of US $9.20 per GDR. Each GDR represents three fully paid-up equity shares of Rs 10 each, issued at Rs 135 per equity share.